Research News

Researchers at Osaka Metropolitan University’s Graduate School of Medicine evaluated whether adding 5-aminosalicylic acid (5-ASA) to vedolizumab therapy helps prevent relapse in ulcerative colitis (UC) and Crohn’s disease (CD). Using a large Japanese claims database, the team found no benefit of 5-ASA in maintaining remission for either UC or CD. These findings suggest that combining 5-ASA with vedolizumab may not be beneficial.

Paper information

Journal: Inflammatory Bowel Diseases
Title: Lack of Efficacy of Concomitant 5-Aminosalicylic Acid with Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis
DOI: 10.1093/ibd/izaf088
Authors: Yu Nishida, Shuhei Hosomi, Koji Fujimoto, Yumie Kobayashi, Rieko Nakata, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara
Published:  21 May 2025
URL: https://doi.org/10.1093/ibd/izaf088

Contact

Yu Nishida
Graduate School of Medicine
Email: d21603q[at]omu.ac.jp

Shuhei Hosomi
Graduate School of Medicine
Email: shuhosomi[at]gmail.com

*Please change [at] to @.